Wellington Management Group
VNDA icon

Wellington Management Group’s Vanda Pharmaceuticals VNDA Stock Holding History

Wellington Management Group’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$220K Buy
+36,000
New +$235K ﹤0.01% 1891
2026
Q1 		– Sell
-178,851
Closed -$1.58M – 2012
2025
Q4 		$1.58M Sell
178,851
-10,196
-5% -$56.1K ﹤0.01% 1647
2025
Q3 		$943K Sell
189,047
-103,448
-35% -$479K ﹤0.01% 1790
2025
Q2 		$1.38M Buy
292,495
+26,607
+10% +$116K ﹤0.01% 1663
2025
Q1 		$1.22M Sell
265,888
-82,958
-24% -$387K ﹤0.01% 1661
2024
Q4 		$1.67M Buy
348,846
+39,195
+13% +$188K ﹤0.01% 1613
2024
Q3 		$1.45M Sell
309,651
-56,107
-15% -$301K ﹤0.01% 1635
2024
Q2 		$2.07M Sell
365,758
-70,009
-16% -$362K ﹤0.01% 1507
2024
Q1 		$1.79M Buy
+435,767
New +$1.74M ﹤0.01% 1541
2023
Q4 		– Sell
-183,798
Closed -$794K – 1931
2023
Q3 		$794K Sell
183,798
-24,591
-12% -$137K ﹤0.01% 1635
2023
Q2 		$1.37M Buy
+208,389
New +$1.34M ﹤0.01% 1554
2022
Q3 		– Sell
-11,358
Closed -$124K – 2159
2022
Q2 		$124K Hold
11,358
– – ﹤0.01% 2028
2022
Q1 		$128K Sell
11,358
-511
-4% -$6.72K ﹤0.01% 2083
2021
Q4 		$187K Buy
+11,869
New +$207K ﹤0.01% 2131
2020
Q1 		– Sell
-28,122
Closed -$461K – 2058
2019
Q4 		$461K Buy
+28,122
New +$425K ﹤0.01% 1867
2017
Q2 		– Sell
-107,313
Closed -$1.5M – 2303
2017
Q1 		$1.5M Sell
107,313
-58,646
-35% -$836K ﹤0.01% 1809
2016
Q4 		$2.65M Buy
+165,959
New +$2.67M ﹤0.01% 1613
2015
Q4 		– Sell
-78,240
Closed -$883K – 2245
2015
Q3 		$883K Sell
78,240
-11,400
-13% -$139K ﹤0.01% 1859
2015
Q2 		$1.14M Hold
89,640
– – ﹤0.01% 1811
2015
Q1 		$834K Sell
89,640
-9,370
-9% -$106K ﹤0.01% 1883
2014
Q4 		$1.42M Sell
99,010
-10,090
-9% -$119K ﹤0.01% 1774
2014
Q3 		$1.13M Sell
109,100
-17,300
-14% -$227K ﹤0.01% 1802
2014
Q2 		$2.04M Hold
126,400
– – ﹤0.01% 1676
2014
Q1 		$2.05M Buy
+126,400
New +$1.8M ﹤0.01% 1685

Other funds holding VNDA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wellington Management Group's VNDA Position: Q2 2026 in Review

Wellington Management Group opened a new position in Vanda Pharmaceuticals (VNDA) in Q2 2026: 36,000 shares worth $220K. The stake represents ﹤0.01% of the portfolio and ranks #1891 among its holdings. This is a return to the name: Wellington Management Group previously reported a position in VNDA as recently as Q4 2025.

Wellington Management Group first reported a position in VNDA in Q1 2014 and has held it in 24 quarters since. The position peaked at $2.65M in Q4 2016. 172 funds tracked by Wall St. Rank hold VNDA as of Q2 2026.

  • Wellington Management Group held 36,000 shares of Vanda Pharmaceuticals worth $220K as of Q2 2026.
  • Vanda Pharmaceuticals was a new Wellington Management Group position in Q2 2026.
  • Vanda Pharmaceuticals made up ﹤0.01% of Wellington Management Group's portfolio in Q2 2026, its #1891 holding.
  • Wellington Management Group first reported a position in Vanda Pharmaceuticals in Q1 2014 and has held it in 24 quarters since.
  • Wellington Management Group's Vanda Pharmaceuticals position peaked at $2.65M in Q4 2016.
  • 172 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2026.

Based on Wellington Management Group's 13F filing for Q2 2026, filed 14 Aug 2026.